US 12,358,879 B2
Heterocyclic compound
Masashi Toyofuku, Kanagawa (JP); Yoshiteru Ito, Kanagawa (JP); Marilena Pira, Kanagawa (JP); and Takahiro Sugimoto, Kanagawa (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 17/766,400
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Oct. 15, 2020, PCT No. PCT/JP2020/038850
§ 371(c)(1), (2) Date Apr. 4, 2022,
PCT Pub. No. WO2021/075476, PCT Pub. Date Apr. 22, 2021.
Claims priority of application No. 2019-191533 (JP), filed on Oct. 18, 2019.
Prior Publication US 2023/0322683 A1, Oct. 12, 2023
Int. Cl. C07D 231/56 (2006.01); A61P 25/28 (2006.01); C07D 405/12 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01)
CPC C07D 231/56 (2013.01) [A61P 25/28 (2018.01); C07D 405/12 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01)] 15 Claims
 
1. A compound represented by the formula

OG Complex Work Unit Chemistry
wherein
R1 is a hydrogen atom, an optionally substituted C1-6 alkyl group,
or an optionally substituted C3-6 cycloalkyl group;
R2 is an optionally substituted C1-6 alkyl group, or an optionally substituted cyclic group;
R3 is an optionally substituted C1-6 alkyl group;
R4 is an optionally substituted C1-6 alkyl group; and
Ring A is an optionally further substituted benzene ring,
or a salt thereof.